RxDoctor Payments Data

Robert Kelly, MD

Internal Medicine · Fort Worth, TXNPI 1619944485

Payments from drug & device makers

$786in general payments, 2019–2025

Across 13 payments — averaging $60.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$593
  • Novo Nordisk$49
  • Pfizer$33
  • Novartis$32
  • E.r. Squibb & Sons, L.L.C.$23
  • Biogen$19
  • plus $38 from 3 others

What the payments were for

  • Speaking & faculty fees$56472%
  • Food & beverage$22228%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$786 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$299,998
Medicare patients
272
Services billed
4,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$161,670
JardianceEmpagliflozin137$126,251
Repatha SureclickEvolocumab81$57,514
OzempicSemaglutide32$46,769
RybelsusSemaglutide24$39,182
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$34,324
Repatha SyringeEvolocumab45$31,450
JanuviaSitagliptin Phosphate20$23,668
FarxigaDapagliflozin Propanediol28$20,928
Praluent PenAlirocumab23$15,976
XareltoRivaroxaban28$15,494
Ezetimibe453$11,846
Lagevrio (Eua)Molnupiravir18$9,717
PremarinEstrogens, Conjugated22$8,072
MyrbetriqMirabegron11$6,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$33$169,742208 claims
Novo NordiskOzempic, Rybelsus$49$85,95256 claims
GSKTrelegy Ellipta$593$34,32447 claims
NovartisEntresto$32$6,82511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →